Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge – Hagens Berman

SAN FRANCISCO, May 22, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is facing a securities class action lawsuit in the Northern District of California, alleging that the company misled investors about its growth potential and ability to capitalize on demand for its cancer treatments. The case, Farberov v. Iovance Biotherapeutics, Inc., et al., centers on statements made between May 9, 2024, and May 8, 2025, a period that includes an expansion from the initial Augu ...